More than twice the risk of failure for patients starting on abacavir with low CD4s or high viral loads, compared with tenofovir
‘Near perfect’ adherence in early stages of Partners PrEP study
Gay men reduce their risk behaviour after HIV diagnosis, studies find, but disagree on how much by
High rate of HCV reinfection after treatment of acute infection in Amsterdam gay men
Is treatment really reducing infections?
At least one in six patients maintains a viral load over one hundred thousand
Long-term HIV infection and poor inflammation control, not treatment, predicts risk of atherosclerosis
Optimising infant HIV treatment in resource-limited settings: when can nevirapine be used?
Six months of nevirapine prophylaxis for breastfeeding infants reduces transmission by 76% if mother not on ART
Partners study expands our knowledge of HIV transmission risk
Modellers examine the cost-effectiveness of PrEP in Africa
Forecasters agree PrEP/microbicides could cut HIV infections in South Africa
Once-daily raltegravir found inferior to twice-daily dosing
Is HIV drug resistance spreading? Early warning signals say 'yes'
Telaprevir works well for people with HIV/HCV co-infection
First pills-versus-gel trial finds US women prefer oral PrEP
Does immune reconstitution contribute to ART-related bone loss?
New data from PrEP study shed light on adherence, bone mineral loss and resistance
